Skyward Specialty Insurance Group reported Q1 2026 results after the close on May 6 that beat estimates on both top and bottom lines — and the headline numbers land at a stock that spent most of the past week sliding toward its lows.
The beat was clear-cut. Adjusted EPS came in at $1.25 versus the $1.12 consensus. Revenue of $475.9 million blew past the $412.8 million estimate. Operating cash flow for the full year is tracking near $534 million. With the stock trading at $43.93 and the trailing P/E at roughly 8.7x, the valuation case for bulls has not diminished. The EV/EBIT factor scores rank in the 70th percentile, confirming the stock screens attractively relative to peers on an earnings basis.
The positioning picture shows shallow short interest that is quietly building. At 3.5% of the free float — up roughly half a percent on the week — shorts are not crowded by any measure. Borrow costs remain almost negligible at 0.44% annualised, and availability is well above 1,000%, meaning there is no friction whatsoever for new short sellers entering the market. That loose borrow market, combined with a sub-4% short position, points to positioning that is more indifferent than hostile. The ORTEX short score of 35.7, sitting in the 40th percentile of the broader universe, reinforces that read. Options lean somewhat defensive, with the put/call ratio at 1.25 — essentially in line with its 20-day mean of 1.24 and a near-zero z-score. Traders went into the print with hedges but without a strong directional bias.
The most telling data ahead of the print came from insiders. The CEO Andrew Robinson purchased a combined 22,100 shares across two tranches on February 27 at prices around $46.50–$46.94, committing just over $1 million of his own capital at prices above the current market. The CFO also stepped in on the same date, alongside an independent director who accumulated a further 5,000 shares through early March. Net insider buying over the 90-day window reached nearly $2.55 million across 54,856 shares — a cluster of conviction purchases from the people closest to the business, made when the stock was meaningfully cheaper. The stock now trades below those acquisition prices at $43.93, which puts those buyers briefly offside even before the Q1 beat.
Analysts broadly remain supportive but have been trimming targets since February. Barclays maintained Overweight in early April but cut to $57 from $63. Keefe, Bruyette & Woods similarly held Outperform while lowering its target from $70 to $65. Both moves reflect wider sector repricing rather than fundamental doubt about the business — every recent action has preserved the positive rating. The consensus target of $60.18 implies roughly 37% upside from the current price, though that figure was last formally updated in early April, before the Q1 earnings release. With the numbers now out and beating on both lines, there is room for targets to be refreshed upward. The EPS momentum factor, which ranks in the 68th percentile on a 90-day basis, supports that possibility.
Peer divergence was notable on the week. Closest correlated peer PLMR fell 12.1% over the same period, while BOW added 3.0%. EG and AFG were roughly flat. SKWD's 3.6% weekly decline therefore tracked the weaker end of its peer group — consistent with the stock pricing in earnings uncertainty rather than any company-specific deterioration.
The earnings call scheduled for May 7 is the immediate focus. Markets now have the hard numbers; what is less clear is management's tone on the Apollo acquisition integration, the degree to which the Uber AV insurance partnership is scaling, and whether the guidance range gets revised upward given the Q1 beat. Those three threads are likely to set the near-term direction.
See the live data behind this article on ORTEX.
Open SKWD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
